Protocol Summary for Out-of-Province Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors

**Protocol Code**  
GINPRRT

**Tumour Group**  
Gastrointestinal

**Contact Physician**  
Dr. Sharlene Gill

**ELIGIBILITY:**
- Well to moderately differentiated advanced neuroendocrine tumors with progressive and or symptomatic carcinoid syndrome despite sandostatin LAR therapy and/or radiographic progressive disease
- Confirmed octreotide-avid disease by octreoscan (for treatment with Lutetium $^{177}$-octreotate) and/or mIBG-avid disease by mIBG scan (for treatment with $^{131}$I-mIBG)
- Not a candidate for curative-intent surgical options
- Ki67 less than or equal to 20% and mitotic count <20/HPF
- Documented approval at BCCA provincial or regional GI conference
- Patient willing to travel to Edmonton for therapy
- Requires out-of-province funding approval (not a BCCA Benefit List drug)

**EXCLUSIONS:**
- Platelets less than 100
- Hemoglobin less than 90
- ECOG PS greater than 1
- Creatinine clearance or glomerular filtrate rate (GFR) less than 50 mL/min

**TESTS:**
- CBC and diff, platelets, electrolytes, creatinine, BUN, bilirubin, AST, LDH, alkaline phosphatase, INR, albumin
- Serum chromogranin A
- 24 urine 5HIAA
- Octreotide and mIBG scan within the past 6 months
- CT/MRI within the past 6 months
TREATMENT:
Up to 4 cycles of therapy are given at minimum intervals of 4 to 6 weeks. Further therapy is subject to re-approval for out-of-province funding.

Patients are referred to the Cross Cancer Institute in Edmonton, AB for consideration of radioisotope therapy. For referral, please forward the following:
- Pathology report(s)
- Operative report(s)
- Consultation note documenting history, comorbidities, medications and ECOG
- Results of recent laboratory and urine tests as listed above
- Octreotide and mIBG scan – images and report (on CD)
- CT/MRI – images and report (on CD)
- Demographics and contact information for the patient

Send by courier to:

Nuclear Medicine Therapy Coordinator
Neuroendocrine Tumor Clinic Coordinator
Cross Cancer Institute
11560 University Avenue
Edmonton, AB  T6G 1Z2

Call GI tumour group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date created: 1 Dec 2013

Date(s) revised:

References: